Eloralintide

New to peptides? Start with what are peptides? and how do peptides work?

Overview

Eloralintide is Eli Lilly's entry in the amylin race — a long-acting, selective amylin receptor agonist for weight management. The selectivity is the distinguishing feature and the reason for the drug's design.

Selective versus non-selective

Amylin receptors are built from a calcitonin receptor core combined with accessory proteins. That architecture means many amylin-mimicking compounds also activate the calcitonin receptor itself, producing effects on bone and calcium metabolism that have nothing to do with appetite. Eloralintide is engineered to target the amylin receptor preferentially and spare the calcitonin receptor, with the aim of a cleaner effect and fewer off-target consequences.

Why Lilly is building it

Lilly already markets tirzepatide and is developing retatrutide. Adding a selective amylin agonist gives it a mechanism that works outside the incretin system entirely — usable alone, or stacked on top of its incretin drugs. Eloralintide is being studied both as monotherapy and in combination with tirzepatide, which tells you how the company sees its role.

Status

Eloralintide is investigational and not approved. Phase 2 results were reported in late 2025 and published in a major medical journal, and the Phase 3 program began enrolling around the end of 2025 and is ongoing. It is not available by prescription or through any legitimate consumer route.

How it works

Amylin signaling

Amylin is released with insulin after eating and acts on receptors in the area postrema of the brainstem — a region positioned to sample the bloodstream directly. Activation slows gastric emptying, suppresses post-meal glucagon, and promotes satiation, so meals end earlier and total intake falls. This is a distinct pathway from GLP-1, with different receptors and a partly different neural circuit.

What selectivity is meant to buy

By concentrating activity at the amylin receptor rather than the shared calcitonin receptor, the intent is to capture the appetite effect while avoiding calcitonin-mediated effects on bone turnover and calcium handling. Whether this translates into a measurably better clinical profile than less selective amylin analogs is an open question that only comparative data can answer — it is a well-reasoned design goal, not yet a demonstrated advantage.

Designed for combination

Because it works outside the incretin system, eloralintide can in principle be added to a GLP-1 or dual agonist without competing at the same receptor. The parallel program testing it alongside tirzepatide is a direct test of whether two independent appetite pathways produce more weight loss than one — the same question CagriSema asks with different molecules.

Clinical evidence

The Phase 2 trial

Lilly reported results from a 48-week Phase 2 trial in 263 adults with obesity or overweight without type 2 diabetes. All treatment arms met the primary endpoint. Mean weight loss ranged from about 9.5% to 20.1% depending on dose, versus roughly 0.4% on placebo. The results were presented at ObesityWeek 2025 and published in The Lancet.

Reading the dose range

That 9.5% to 20.1% spread is the most informative part of the result, and it is more useful than the headline top-line figure. It shows a clear dose-response — more drug, more weight loss — and it frames the central question for Phase 3: the highest doses approach the range of the leading incretin drugs, while the lower doses trade efficacy for tolerability. Gastrointestinal side effects were mild to moderate and, at the lower doses, occurred at rates similar to placebo. Where the drug ultimately lands commercially depends on which point on that curve turns out to be the one people can live with.

What Phase 3 has to show

The Phase 3 program began enrolling around the end of 2025. It will need to confirm the weight loss at scale, characterize safety in far larger and more varied populations, and establish durability over longer periods. No Phase 3 results are available.

Evidence tier

This is Phase 2 evidence: randomized, placebo-controlled, peer-reviewed, and genuinely encouraging — but mid-stage, in a modest number of carefully selected participants, and not yet reviewed by any regulator.

Safety & status

Reported effects

The most common adverse events in Phase 2 were mild to moderate gastrointestinal symptoms, with incidence in the lower-dose arms similar to placebo. That tolerability profile, particularly at doses still producing double-digit weight loss, is the main reason the program attracted attention.

As with every drug at this stage, the safety picture is incomplete by definition. A 48-week trial in a few hundred people cannot detect rare events, cannot characterize risk in people with multiple coexisting conditions, and cannot say anything about multi-year use. Amylin analogs as a class have not been used at scale for chronic weight management, so class-level long-term effects are also not yet known.

Status

Eloralintide is not FDA-approved and is not commercially available. It cannot be obtained legitimately outside a clinical trial. Products marketed under this name or its development code by research-chemical vendors are unregulated, unverified, and bear no relationship to the material used in the trials described above.

See also petrelintide, the closest competing amylin program, and cagrisema, which pairs an amylin analog with a GLP-1 drug.

The amylin analogs compared

Amylin is released with insulin and signals fullness through the brainstem — a pathway independent of GLP-1. That independence is why this class is considered the most promising frontier after the incretin drugs, either alone or stacked with them.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025. Peer-reviewed study
2. Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025. Peer-reviewed study
3. Bhattachar S, Tham LS, Tidemann-Miller B, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. 2026. Peer-reviewed study
4. Briere DA, Qu H, Lansu K, et al.. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025. Peer-reviewed study
5. Billings LK, Hsia S, Bays H, et al.. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025. Peer-reviewed study
6. Bhattachar S, Tham LS, Tidemann-Miller B, et al.. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. 2026. Peer-reviewed study